Medication info
Besilsartan Q Tablet 5/100/10 mg (Amlodipine, Losartan, Rosuvastatin)

Besilsartan Q Tablet 5/100/10 mg (Amlodipine, Losartan, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletLosartan Potassium›100mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Pale pink oval film-coated tablets
Packaging
PTP - 30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202502493 · Approved 2025.09.19

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine should be administered only to adults, and the dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination in adults is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the expected degree of target attainment with the combination compared with the individual agents. The usual dose is this medicine 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ○ Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (e.g., creatinine clearance 20∼50mL/min), but use of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. ○ Patients with reduced effective intravascular volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced effective intravascular volume (e.g., patients receiving treatment with high-dose diuretics). (See section 1. Warnings under Precautions for Use.) ○ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ○ Older adults: In older adults aged 75 years or older, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients. Patients taking the amlodipine/losartan combination concomitantly with rosuvastatin may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • stage 2 hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
View approved original text

This medication is used for patients who need to take a combination of amlodipine and losartan and rosuvastatin together. The Amlodipine/Losartan combination is used as the initial treatment for patients with essential hypertension who have not adequately controlled their blood pressure with monotherapy, or for patients with stage 2 hypertension to achieve targeted blood pressure. Rosuvastatin is administered as an adjunct when management with diet alone is insufficient in patients with hypercholesterolemia and mixed hyperlipidemia and helps slow the progression of atherosclerosis. Moreover, it reduces the risk of stroke, myocardial infarction, and revascularization in patients at high risk for cardiovascular diseases. Therefore, this medication is used to effectively manage hypertension and hyperlipidemia.

How to take

Adult dose

This medicine should be administered only to adults, and the dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination in adults is 1 tablet once daily, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the expected degree of target attainment with the combination compared with the individual agents. The usual dose is this medicine 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ○ Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (e.g., creatinine clearance 20∼50mL/min), but use of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. ○ Patients with reduced effective intravascular volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced effective intravascular volume (e.g., patients receiving treatment with high-dose diuretics). (See section 1. Warnings under Precautions for Use.) ○ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ○ Older adults: In older adults aged 75 years or older, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which provides control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin at a dose of 40 mg is contraindicated in some of these patients. Patients taking the amlodipine/losartan combination concomitantly with rosuvastatin may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This medication can cause serious side effects to the fetus if taken during pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Caution is required as hypotension may occur when administered to patients with decreased blood volume. Patients with known allergies to any of the components or those with a history of certain liver or kidney diseases or angioedema should not use it. Elderly patients, those with hypotension, or patients with impaired liver or kidney function should use this drug with caution and regularly monitor blood pressure and kidney function. If symptoms of muscle pain or weakness occur, consult a doctor immediately, and discontinue use if severe. This medication may affect liver function; therefore, caution is warranted if there are liver diseases or abnormal liver function test results. There may be interactions with other medications, so inform your healthcare provider if you are taking any other medications. Particularly, caution should be taken when combined with potassium-sparing diuretics or potassium supplements, as blood potassium levels may become dangerously elevated. This drug has blood pressure-lowering effects, which may cause dizziness or fainting; thus, caution is needed when driving or operating machinery. If any abnormal symptoms occur during use, notify medical personnel immediately and seek appropriate action.

Side effects

Craniosynostosis, anuria, hypotension, renal failure, upper respiratory infection, dizziness, dyspepsia, lower gastrointestinal bleeding, orthostatic dizziness, presyncope, rhabdomyolysis, pancreatic cancer, dizziness, headache, drowsiness, cerebral infarction, weakness, chest discomfort, chest pain, early satiety, peripheral edema, pit edema, abdominal discomfort, nausea, gastroesophageal reflux disease, constipation, pruritus, urticaria, palpitations, flushing, orthostatic hypotension, facial flushing, dyspnea, cough, conjunctival hyperemia, frequent urination, angioedema, diabetes, constipation, nausea, abdominal pain, pruritus, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, headache, fatigue, edema, dizziness, drowsiness, abdominal pain, nausea, weakness, lethargy, pain, weight gain, weight loss, hypotension, vasculitis, tension hypertension, sensory impairment, sensory abnormalities, peripheral neuropathy, syncope, dysgeusia, tremor, extrapyramidal disorder, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, gastritis, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, cough, dyspnea, rhinitis, hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, tinnitus, visual disturbances, increased urinary frequency, urinary dysfunction, enuresis, hepatitis, jaundice, elevated liver enzymes, pruritus, rash, angioedema, erythema multiforme, myocardial infarction, arrhythmia, chest pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, erythematous rash, papular rash, heaviness in the head, warmth, impaired glucose tolerance, weakness, facial edema, fever, orthostatic effect, syncope, angina, second-degree atrioventricular block, cerebrovascular accident, hypotension, myocardial infarction, atrial fibrillation, palpitations, bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation, appetite loss, toothache, dry mouth, flatulence, gastritis, vomiting, anemia, gout, upper limb pain, hip pain, joint swelling, knee pain, myasthenia, anxiety, anxiety disorders, ataxia, confusion, depression, nightmares, sensory reduction, decreased libido, memory impairment, migraine, neuroexcitability, panic disorder, sleep disorders, hypersomnia, tremor, dizziness, bronchitis, pharyngeal discomfort, epistaxis, rhinitis, respiratory congestion, chest discomfort, hair loss, dermatitis, dry skin, petechiae, erythema, flushing, photosensitivity, itching, rash, sweating, urticaria, blurred vision, burning eyes, neuralgia, conjunctivitis, dysgeusia, tinnitus, decreased vision, erectile dysfunction, enuresis, frequent urination, urethritis, angioedema, vasculitis, anaphylactic syndrome, liver dysfunction, hepatitis, intestinal vascular edema, lethargy, anemia, thrombocytopenia, myalgia, feelings of weakness, elevated creatine kinase, dysgeusia, dry cough, erythroderma, hyperkalemia, hyponatremia, elevated ALT, acute kidney injury, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale pink oval film-coated tablets

Package unit

PTP - 30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.